# TB-500 side effects, safety signals, and the tumor-angiogenesis question > TB-500 side effects: no controlled human safety profile exists for the Ac-LKKTETQ fragment. The tumor-angiogenesis signal, the null mdx muscle result, the identity and purity gaps — the honest risk record on TB-500, every claim cited. The flagged net surfaced first: no human safety profile for the fragment, a pro-angiogenic mechanism that doubles as the oncologic concern, and a notable null muscle result. ## The flagged net, read first TB-500 side effects cannot be stated from a human safety database, because none exists for the Ac-LKKTETQ fragment. No controlled clinical trial has characterized its adverse-event profile, its dose-limiting toxicities, or its long-term safety in people [15]. What the record does contain is a coherent theoretical concern that runs through the same mechanism the compound is valued for — and that concern is routed to the top of this page rather than the bottom. The one human safety signal that exists is reassuring but off-target: intravenous full-length thymosin β4 was well tolerated to 1260 mg in a Phase 1 study, with no dose-limiting toxicities and only mild, infrequent adverse events [6]. That study used the full-length protein, by the intravenous route, in 40 volunteers — it does not transfer to the fragment, to community routes, or to chronic use. Treat it as a single data point on the parent protein, clearly labeled, not as a safety clearance for TB-500. ## Does TB-500 cause cancer or promote tumor growth? Thymosin β4 is overexpressed in several cancers — including pancreatic — and is implicated in metastasis and tumor angiogenesis [7][8]. The mechanistic logic is direct and uncomfortable: the same pro-migratory, pro-angiogenic properties that accelerate wound repair could, in principle, support tumor cell migration and tumor blood supply. A study of human pancreatic cancer cells found Tβ4 overexpressed and linked to proliferation- and invasion-related behavior [8]. Human safety data for the fragment are scarce [15], so this remains a theoretical but well-grounded concern rather than a quantified human risk — which is exactly why it is flagged rather than dismissed. ## Does TB-500 promote angiogenesis, and is that a safety concern? Thymosin β4 promotes endothelial migration and new-vessel formation [5][14]. In a repair context that is beneficial — vessels rebuild damaged tissue. In an oncologic context the same pathway can support a tumor's blood supply, which is the basis of the tumor-angiogenesis safety concern [7]. This is the board's clearest example of a single trace feeding two pads: the benefit and the risk are the same biology, read in two settings. ## What are the side effects of TB-500? No controlled human safety profile exists for the heptapeptide, so a conventional side-effect list cannot be compiled from trial data [15]. Intravenous full-length Tβ4 was well tolerated to 1260 mg in a Phase 1 study [6], but the principal documented concern is the tumor-angiogenesis signal [7][8]. Research-grade identity and purity are a separate, recurring problem: unregulated material may not be the correct sequence or purity, which complicates any safety interpretation. ## Is TB-500 safe? TB-500 has no controlled human safety profile for the heptapeptide, so it cannot be called safe on the basis of human evidence [15]. The most-cited concern is the thymosin β4 tumor-angiogenesis signal [7][8]; the most-cited reassurance is a single Phase 1 study of the full-length protein, well tolerated to 1260 mg intravenously [6]. The honest summary is that the fragment's safety in humans is uncharacterized, and the existing signal points toward caution, not clearance. ## Is TB-500 safe for long-term use? Long-term human safety of the TB-500 fragment is unknown — no chronic controlled human trials exist [15]. The tumor-angiogenesis signal [7][8] and unregulated product quality are the main reasons that community "loading then maintenance" protocols are not validated. The longest controlled exposure in the record is an animal study: six months of thymosin β4 in mdx mice, which raised regenerating-fiber counts without improving strength or reducing fibrosis [9] — a chronic-dosing result that is null on function, not a human safety endorsement. ## What are the negative effects of TB-500? Beyond the unknown human safety profile, the literature carries explicit counter-evidence. In dystrophin-deficient mdx mice, chronic thymosin β4 increased regenerating fibers but did not improve muscle strength, cardiac function, or fibrosis [9]. The tumor-overexpression and pro-angiogenesis findings are the most-cited theoretical harms [7][8]. And a 2026 review placed TB-500 among unapproved peptides operating largely outside regulatory oversight, with the potential for serious harm and scarce human safety data [15]. These are the negatives the board flags rather than smooths over. ## The identity and purity problem A risk specific to TB-500 is that the material may not be what the label says. "TB-500" in commerce denotes the 889 Da Ac-LKKTETQ fragment, but much marketing leans on full-length thymosin β4 data [5][10], and unregulated supply does not guarantee correct sequence, purity, or even fragment-versus-full-length identity. This complicates both safety and any interpretation of anecdotal results: if the molecule in a vial is uncertain, so is everything reported about it. The structural and pharmacological record is only as meaningful as the identity of the substance it describes. --- A cool-green research board for the TB-500 record — the Ac-LKKTETQ fragment routed as its own net apart from the full-length thymosin beta-4 it is sold as, the empty human-trial pad left open, the tumor-angiogenesis trace flagged and the FDA 503A standing read first; no clinic solders this board and nothing here is dispensed or sold.